Iain Thomas

Iain Thomas heads Cambridge Enterprise’s Life Science team. The team is responsible for technology in fields as diverse as therapeutics, diagnostics, biofuels, IVF and agritech. Spin-outs from Cambridge University include Mission Therapeutics, Cambridge Epigenetix, XO1 Therapeutics, Z-factor, Phoremost, Predictimmue and Polyprox; XO1 was sold to Janssen for an undisclosed sum. Iain led discussions with GSK in respect of the University of Cambridge–GSK open innovation drug discovery initiative based at the Stevenage Bioscience Catalyst, founded (with others) Apollo Therapeutics an innovative vehicle for developing early stage therapeutic opportunities from three Universities (Cambridge, University College London and Imperial College) and led the creation of Ceres a funding partnership of technology in the Agritech sector.